Skip to main content

SCLC

6
Pipeline Programs
9
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Design Pharmaceuticals
1 program
1
Topotecan - usualPhase 2/31 trial
Active Trials
NCT07145333Active Not Recruiting600Est. Oct 2026
Astellas
AstellasChina - Shenyang
1 program
1
OSI-211Phase 21 trial
Active Trials
NCT00046787Completed47Est. Feb 2003
Dizal Pharma
Dizal PharmaChina - Shanghai
1 program
1
golidocitinib with PD-1 inhibitorsPhase 21 trial
Active Trials
NCT07110103Recruiting20Est. Jun 2028
Y-mAbs Therapeutics
Y-mAbs TherapeuticsNY - New York
2 programs
1
1
NivatrotamabPhase 1/2Monoclonal Antibody1 trial
GD2-SADA:177Lu-DOTA ComplexPhase 11 trial
Active Trials
NCT05130255Recruiting60Est. Apr 2027
NCT04750239Terminated3Est. Apr 2022
Innovent Biologics
Innovent BiologicsChina - Jiangsu
1 program
1
CarboplatinPhase 11 trial
Active Trials
NCT05026593Completed60Est. Jun 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
SRSN/A1 trial
Active Trials
NCT03297788Completed56Est. Dec 2023
Zai Lab
Zai LabCA - South SF
1 program
ZL-1310PHASE_11 trial
Active Trials
NCT06179069Recruiting339Est. Jul 2027
Labcorp
LabcorpBURLINGTON, NC
1 program
ZL-1310PHASE_1
Design Therapeutics
1 program
Topotecan - usualPHASE_2_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Design PharmaceuticalsTopotecan - usual
Dizal Pharmagolidocitinib with PD-1 inhibitors
AstellasOSI-211
Y-mAbs TherapeuticsNivatrotamab
Zai LabZL-1310
Y-mAbs TherapeuticsGD2-SADA:177Lu-DOTA Complex
Innovent BiologicsCarboplatin
Heidelberg PharmaSRS

Clinical Trials (8)

Total enrollment: 1,185 patients across 8 trials

NCT07145333Design PharmaceuticalsTopotecan - usual

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Start: Aug 2025Est. completion: Oct 2026600 patients
Phase 2/3Active Not Recruiting
NCT07110103Dizal Pharmagolidocitinib with PD-1 inhibitors

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Start: Oct 2025Est. completion: Jun 202820 patients
Phase 2Recruiting
NCT00046787AstellasOSI-211

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Start: Sep 2002Est. completion: Feb 200347 patients
Phase 2Completed
NCT04750239Y-mAbs TherapeuticsNivatrotamab

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Start: Aug 2021Est. completion: Apr 20223 patients
Phase 1/2Terminated
NCT06179069Zai LabZL-1310

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Start: Jan 2024Est. completion: Jul 2027339 patients
Phase 1Recruiting
NCT05130255Y-mAbs TherapeuticsGD2-SADA:177Lu-DOTA Complex

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Start: Nov 2022Est. completion: Apr 202760 patients
Phase 1Recruiting
NCT05026593Innovent BiologicsCarboplatin

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Start: Sep 2021Est. completion: Jun 202360 patients
Phase 1Completed
NCT03297788Heidelberg PharmaSRS

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Start: Dec 2017Est. completion: Dec 202356 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,185 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.